RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
41 hedge funds and large institutions have $28.7M invested in RVL Pharmaceuticals plc Ordinary Shares in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
14% more funds holding
Funds holding: 36 → 41 (+5)
2% more capital invested
Capital invested by funds: $28.2M → $28.7M (+$484K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.18% less ownership
Funds ownership: 25.52% → 25.34% (-0.18%)
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Scoggin Management
New York
|
+$600K |
| 2 |
IA
Insight Advisors
Newtown,
Pennsylvania
|
+$45.4K |
| 3 |
LPL Financial
San Diego,
California
|
+$25.5K |
| 4 |
Jane Street
New York
|
+$21.3K |
| 5 |
Squarepoint
New York
|
+$13.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$655K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$160K |
| 3 |
Morgan Stanley
New York
|
-$46.9K |
| 4 |
VF
Virtu Financial
New York
|
-$45K |
| 5 |
Renaissance Technologies
New York
|
-$21.4K |
RVLP Hedge Fund Activity: Q1 2023 in Review
41 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q1 2023, worth a combined $28.7M — up 1.7% from $28.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RVLP positions and 2 closed out — a net gain of 6 holders — while 3 added to existing stakes and 9 trimmed.
The largest buyer was Scoggin Management, opening a new position worth an estimated $600K. The largest seller was AIGH Capital Management, cutting an estimated $655K.
- 41 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q1 2023, up from 36 in Q4 2022.
- Funds reported $28.7M of RVL Pharmaceuticals plc Ordinary Shares stock for Q1 2023, up 1.7% quarter-over-quarter.
- 8 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q1 2023 and 2 closed out, a net change of +6 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q1 2023 was Scoggin Management, an estimated $600K added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q1 2023 was AIGH Capital Management, an estimated $655K sold.
Based on aggregated 13F filings for Q1 2023.